Basal cell nevus syndrome (BCNS), also known as Gorlin syndrome, is a rare autosomal dominant genetic disorder that affects the skin, endocrine system, nervous system, eyes, bones, and confer susceptibility to various forms of cancers, especially basal cell carcinoma (BCC). The approximate prevalence of basal cell nevus syndrome is reported to be from 1/57,000 to 1/256,000, with a male-to-female ratio of 1:1. It is characterized by five major components, including multiple nevoid basal cell carcinomas, jaw cysts, congenital skeletal abnormalities, ectopic calcifications, and plantar or palmar pits. Other features may also be present.
Clinical diagnosis relies on specific criteria including careful oral and skin examinations, chest and skull radiographs, panoramic radiographs of the jaw, magnetic resonance imaging of the brain, and pelvic ultrasonography in women. Treatments may include surgery for BCC when the number of lesions is limited, laser ablation, photodynamic therapy and topical chemotherapy. BCNS patients should strictly avoid excessive sun exposure. About 5-10% of the patients develop medulloblastoma, which may be a potential cause of early death.
Mutations in the PTCH1 gene are associated with basal cell nevus syndrome. PTCH1 is a tumor suppressor gene, and mutations in this gene prevent the production of patched-1 protein or lead to the production of an abnormal version of this receptor, which leads to uncontrolled proliferation of the cells. Mutations in PTCH2 and SUFU genes have also been identified in BCNS patients. Both these genes are involved in the hedgehog signaling pathway that plays an important role in cellular proliferation during development.